This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Analysts Estimate Sorrento Therapeutics (SRNE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Sorrento Therapeutics (SRNE) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Sorrento Therapeutics (SRNE) stock based on the movements in the options market lately.
Will Sorrento Therapeutics (SRNE) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for September 8th
by Zacks Equity Research
AU, INTZ, RIO, SRNE, and PRTH have been added to the Zacks Rank #5 (Strong Sell) List on September 8, 2021
Celsion (CLSN) COVID Vaccine Effective in Pre-Clinical Studies
by Zacks Equity Research
Celsion (CLSN) announces data from pre-clinical studies for its investigational vaccine platform as a potential treatment for COVID-19.
Sorrento's (SRNE) COVID Vaccine Effective in Pre-Clinical Study
by Zacks Equity Research
Sorrento (SRNE) announces data from pre-clinical study for its investigational mRNA COVID vaccine. The company also in-licensed rights to highly potent main protease inhibitors against COVID variants.
Sorrento (SRNE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Sorrento (SRNE) will provide updates on earnings and revenues when it releases second-quarter 2021 results.
Will Sorrento Therapeutics (SRNE) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moving Average Crossover Alert: Sorrento Therapeutics (SRNE)
by Zacks Equity Research
Sorrento Therapeutics (SRNE) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
New Strong Sell Stocks for March 31st
by Zacks Equity Research
AROW, BGS, KEX, SRNE, and TOSYY have been added to the Zacks Rank #5 (Strong Sell) List on March 31, 2021
Sorrento Therapeutics (SRNE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Sorrento Therapeutics (SRNE) closed at $10.97 in the latest trading session, marking a -0.32% move from the prior day.
Sorrento Therapeutics (SRNE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sorrento Therapeutics (SRNE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Sorrento Therapeutics (SRNE) closed at $13.98, marking a -0.71% move from the previous day.
Sorrento (SRNE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Sorrento (SRNE) will provide updates on sales, earnings and pipeline when it reports fourth-quarter 2020 results.
Do Options Traders Know Something About Sorrento (SRNE) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Sorrento (SRNE) stock based on the movements in the options market lately.
Sorrento Therapeutics (SRNE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Sorrento Therapeutics (SRNE) closed the most recent trading day at $7.03, moving -0.57% from the previous trading session.
Company News for Dec 24, 2020
by Zacks Equity Research
Companies in the news are: SUPN, PLTR, JAGX, SRNE
Is the Options Market Predicting a Spike in Sorrento Therapeutics (SRNE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Sorrento Therapeutics (SRNE) stock based on the movements in the options market lately.
Will Sorrento Therapeutics (SRNE) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sorrento (SRNE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Sorrento (SRNE) will provide updates on earnings and revenues when its releases third-quarter 2020 results.
Sorrento Therapeutics (SRNE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Sorrento Therapeutics (SRNE) closed at $7.16, marking a +1.13% move from the previous day.
Sorrento Therapeutics (SRNE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Sorrento Therapeutics (SRNE) closed at $7.92, marking a -1.98% move from the previous day.
Sorrento Therapeutics (SRNE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Sorrento Therapeutics (SRNE) closed the most recent trading day at $11.29, moving +0.98% from the previous trading session.
Sorrento & ViralClear Explore Combination Coronavirus Treatments
by Zacks Equity Research
Sorrento (SRNE) collaborates with ViralClear Pharmaceuticals to evaluate the combination of antibody and antiviral assets against COVID-19.
Company News for Sep 30, 2020
by Zacks Equity Research
Companies In The News Are: SRNE, FIT, GOOGL, NIO, BYND, WMT.